全文获取类型
收费全文 | 25767篇 |
免费 | 2054篇 |
国内免费 | 101篇 |
专业分类
耳鼻咽喉 | 262篇 |
儿科学 | 503篇 |
妇产科学 | 311篇 |
基础医学 | 3670篇 |
口腔科学 | 475篇 |
临床医学 | 3240篇 |
内科学 | 5852篇 |
皮肤病学 | 512篇 |
神经病学 | 2538篇 |
特种医学 | 794篇 |
外国民族医学 | 3篇 |
外科学 | 3687篇 |
综合类 | 248篇 |
现状与发展 | 1篇 |
一般理论 | 11篇 |
预防医学 | 1686篇 |
眼科学 | 401篇 |
药学 | 1698篇 |
中国医学 | 73篇 |
肿瘤学 | 1957篇 |
出版年
2023年 | 157篇 |
2022年 | 302篇 |
2021年 | 655篇 |
2020年 | 437篇 |
2019年 | 687篇 |
2018年 | 791篇 |
2017年 | 564篇 |
2016年 | 605篇 |
2015年 | 724篇 |
2014年 | 962篇 |
2013年 | 1244篇 |
2012年 | 2007篇 |
2011年 | 2172篇 |
2010年 | 1068篇 |
2009年 | 1006篇 |
2008年 | 1627篇 |
2007年 | 1659篇 |
2006年 | 1548篇 |
2005年 | 1556篇 |
2004年 | 1396篇 |
2003年 | 1224篇 |
2002年 | 1225篇 |
2001年 | 282篇 |
2000年 | 252篇 |
1999年 | 285篇 |
1998年 | 258篇 |
1997年 | 197篇 |
1996年 | 138篇 |
1995年 | 139篇 |
1994年 | 104篇 |
1993年 | 107篇 |
1992年 | 184篇 |
1991年 | 169篇 |
1990年 | 151篇 |
1989年 | 138篇 |
1988年 | 142篇 |
1987年 | 137篇 |
1986年 | 143篇 |
1985年 | 145篇 |
1984年 | 117篇 |
1983年 | 97篇 |
1982年 | 101篇 |
1981年 | 98篇 |
1980年 | 84篇 |
1979年 | 78篇 |
1978年 | 72篇 |
1977年 | 66篇 |
1976年 | 53篇 |
1974年 | 50篇 |
1972年 | 47篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
21.
Nephronophthisis related to homozygous NPHP1 gene deletion as a cause of chronic renal failure in adults. 总被引:1,自引:0,他引:1
22.
Vincent Chung Liang Liu Zhaoxiang Bian Zhongzhen Zhao Wai Leuk Fong Wan Fung Kum Jing Gao Min Li 《Movement disorders》2006,21(10):1709-1715
The objective of this study is to assess the efficacy and safety of herbal medicines (HMs), as a monotherapy or adjunct therapy, compared to placebo or conventional approaches in the treatment of idiopathic Parkinson's disease (PD). We conducted a systematic review of randomized controlled trials from both conventional and alternative medicine sources. Outcome measures were overall improvement, quality of life, reduction of levodopa dose, and adverse events. Nine studies were included, each testing a different HM. Six of the trials had limited internal validity due to major flaws in design, including the lack of proper randomization; insufficient blinding; unclear inclusive criteria in terms of diagnostic criteria, baseline staging, and duration of disease; lack of proper sample size calculation; and insufficient data analysis. Imbalances in gender and ethnicity among the patients in the included trials were observed. No major adverse events emerged, and no specific pattern was detected from the trials describing such data. In addition to major methodological defects, heterogeneity in (1) HM tested, (2) control treatment, and (3) outcome measure hindered in-depth data analysis and synthesis. Current evidence is insufficient to evaluate the efficacy and safety of various HMs. Further studies with improved trial design and reporting, with assessment on cost-effectiveness, quality of life, and qualitative data are warranted. 相似文献
23.
R G Jones J W Bass M E Weisse J M Vincent 《The Pediatric infectious disease journal》1991,10(8):557-559
We tested the urine of 30 infants 6 weeks to 7 months of age after they received standard 10-micrograms (0.5-ml) doses of HbOC (HibTITER) Haemophilus influenzae b (Hib) conjugate vaccine for the presence of Hib antigenuria using a commercially available latex particle agglutination assay (Directigen). Urines were collected within 1 hour, from 1 to 3 hours, at 24 hours and at 3, 6 and 9 days after vaccine administration and reactions were quantitated from 0 to 3+. In contrast to previous studies in older children which showed little or no antigenuria following HbOC vaccination, our study shows that in infants intense Hib antigenuria is evident within 2 to 3 hours and persists 3 days after vaccine administration and that less intense antigenuria may be detected in some infants for several days. With efficacious vaccines now being used in 2- to 6-month-old infants, invasive Hib disease may soon be limited to infants of this age just before their seroconversion. It should be recognized that antigenuria occurs for several days after vaccination with Hib conjugate vaccines and that it could be erroneously interpreted as evidence of invasive Hib infection. 相似文献
24.
Effect of periodontal therapy on specific antibody responses to suspected periodontopathogens 总被引:1,自引:0,他引:1
J W Vincent W A Falkler W C Cornett J B Suzuki 《Journal of clinical periodontology》1987,14(7):412-417
The effects of clinically successful periodontal therapy were studied in juvenile periodontitis (JP) and rapidly progressive periodontitis (RP) patients and compared with periodontally healthy subjects (HS). Serum samples were obtained in 35 HS prior to the study and in 12 of these subjects 3-4 years later. Serum samples were obtained from 50 JP patients initially, 9 subjects immediately following surgical therapy and 29 of these subjects 3-4 years later. RP patients provided 46 initial serum samples, 9 following therapy and 27 samples 3-4 years later. Antibody levels were determined utilizing a standardized enzyme-linked immunosorbent assay with Bacteroides gingivalis, B. ochracea, Fusobacterium nucleatum and Actinobacillus actinomycetemcomitans serving as antigens. The JP patients showed an initial rise in antibody levels immediately following therapy followed by a significant decrease in antibody levels 3 to 4 years later. The RP patients did not show an early change in antibody levels but by 3 to 4 years post-therapy, antibody levels had significantly decreased. However, during this study, the antibody levels of JP and RP patients remained significantly higher when compared with HS patients. 相似文献
25.
26.
27.
5-Amino-4-imidazolecarboxamide (AICA) riboside, the nucleoside corresponding to AICA ribotide (AICAR or ZMP), an intermediate of the de novo pathway of purine biosynthesis, was found to exert a dose-dependent inhibition on gluconeogenesis in isolated rat hepatocytes. Production of glucose from lactate-pyruvate mixtures was half-maximally inhibited by approximately 100 microM and completely suppressed by 500 microM AICA riboside. AICA riboside also inhibited the production of glucose from all other gluconeogenic precursors investigated, i.e., fructose, dihydroxyacetone, and L-proline. Measurements of intermediates of the glycolytic-gluconeogenic pathway showed that AICA riboside provoked elevations of triose phosphates and fructose-1,6-bisphosphate and decreases in fructose-6-phosphate and glucose-6-phosphate. The effects of AICA riboside persisted when the cells were washed 10 min after its addition but were suppressed by 5-iodotubercidin, an inhibitor of adenosine kinase. AICA riboside provoked a dose-dependent buildup of normally undetectable Z nucleotides. After 20 min of incubation with 500 microM AICA riboside, ZMP, ZTP, and ZDP reached 3, 0.3, and 0.1 mumol/g cells, respectively. Concentrations of ATP were not significantly modified by addition of up to 500 microM AICA riboside when the cells were incubated with lactate-pyruvate but decreased with fructose or dihydroxyacetone. The activity of rat liver fructose-1,6-bisphosphatase was inhibited by ZMP with an apparent Ki of 370 microM. It is concluded that AICA riboside exerts a suppressive effect on gluconeogenesis because it provokes an accumulation of ZMP, which inhibits fructose-1,6-bisphosphatase.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
28.
Pascale Jolliet Stéphane Nion Gwena?lle Allain-Veyrac L Tilloy-Fenart Dorothée Vanuxeem Vincent Berezowski Roméo Cecchelli 《Pharmacological research》2007,56(1):11-17
PURPOSE: The objective of the current study was to determine the ability of some antiemetic compounds to cross the blood-brain barrier (BBB) and thereby to determine possible side effects of compounds for the central nervous system (CNS). METHODS: We compared the brain penetration of some antiemetic compounds using an in vitro BBB model consisting in brain capillary endothelial cells co-cultured with primary rat glial cells. RESULTS: This study clearly demonstrated that the metopimazine metabolite, metopimazine acid, has a very low brain penetration, lower than metopimazine and even less than the other antiemetic compounds tested in this study. CONCLUSIONS: The poor brain penetration of metopimazine acid, metopimazine biodisponible form, seems very likely related to the clinically observed difference in therapeutic and safety profile. 相似文献
29.
Practical management of patients with non-small-cell lung cancer treated with gefitinib. 总被引:7,自引:0,他引:7
Neelam T Shah Mark G Kris William Pao Leslie B Tyson Barbara M Pizzo Murk-Hein Heinemann Leah Ben-Porat Dana L Sachs Robert T Heelan Vincent A Miller 《Journal of clinical oncology》2005,23(1):165-174
PURPOSE: The use of gefitinib, the first drug approved to inhibit the epidermal growth factor receptor tyrosine kinase, is indicated in patients with non-small-cell lung cancer with tumors progressive after chemotherapy. The unique mechanism of action of this agent leads to distinctive patterns of response and toxicity in persons with lung cancer. Many of the principles of management relevant to gefitinib are distinct from those with conventional cytotoxic drugs. To meet this need, we present practical guidelines on the use of gefitinib in patients with non-small-cell lung cancer. METHODS: This article reviews gefitinib's indications, dosing, response phenomena, and patterns of relapse in individuals with radiographic response. RESULTS: We present our recommendations for the management of rash and diarrhea caused by this agent. CONCLUSION: This information can guide practitioners and help them inform their patients about what to expect when they receive gefitinib. 相似文献
30.
Aisling Mary McMahon Fardod O'Kelly Kheng Tian Lim Narayanasamy Ravi John Vincent Reynolds 《Patient safety in surgery》2009,3(1):19
Esophageal perforation is associated with a significant risk of morbidity and mortality. We report herein a case of lye-induced
esophageal perforation managed successfully by employing endoscopic T-tube placement with a successful outcome. 相似文献